^
    Back
    Association details:
    Biomarker:EZH2 mutation
    Cancer:Lymphoma
    Drug Class:EED inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-I 2020
    Title:

    Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED)

    Published date:
    04/28/2020
    Excerpt:
    ...in Pfeiffer and Karpas-422 lymphoma cell lines carrying an EZH2 mutation...UM-EEDi-5285 is capable of achieving complete and durable tumor regression in the KARPAS-422 xenograft model in mice at well-tolerated dose-schedules...